KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Net (2020 - 2022)

Recursion Pharmaceuticals' Receivables - Net history spans 3 years, with the latest figure at $21000.0 for Q2 2022.

  • For Q2 2022, Receivables - Net fell 57.14% year-over-year to $21000.0; the TTM value through Jun 2022 reached $21000.0, down 57.14%, while the annual FY2021 figure was $34000.0, 78.21% down from the prior year.
  • Receivables - Net reached $21000.0 in Q2 2022 per RXRX's latest filing, down from $34000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $156000.0 in Q4 2020 to a low of $21000.0 in Q2 2022.
  • Average Receivables - Net over 3 years is $57000.0, with a median of $34000.0 recorded in 2021.
  • Peak YoY movement for Receivables - Net: crashed 78.21% in 2021, then tumbled 52.11% in 2022.
  • A 3-year view of Receivables - Net shows it stood at $156000.0 in 2020, then plummeted by 78.21% to $34000.0 in 2021, then plummeted by 38.24% to $21000.0 in 2022.
  • Per Business Quant, the three most recent readings for RXRX's Receivables - Net are $21000.0 (Q2 2022), $34000.0 (Q1 2022), and $34000.0 (Q4 2021).